about
Trial watch: Dendritic cell-based anticancer therapyBy inhibiting snail signaling and miR-23a-3p, osthole suppresses the EMT-mediated metastatic ability in prostate cancer.Current and emerging therapies for bone metastatic castration-resistant prostate cancer.Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Tasquinimod: a novel drug in advanced prostate cancer.
@en
Tasquinimod: a novel drug in advanced prostate cancer.
@nl
type
label
Tasquinimod: a novel drug in advanced prostate cancer.
@en
Tasquinimod: a novel drug in advanced prostate cancer.
@nl
prefLabel
Tasquinimod: a novel drug in advanced prostate cancer.
@en
Tasquinimod: a novel drug in advanced prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Tasquinimod: a novel drug in advanced prostate cancer.
@en
P2093
Hendrik van Poppel
Jacobus Burggraaf
Susanne Osanto
P2860
P304
P356
10.2217/FON.13.136
P407
P577
2013-09-01T00:00:00Z